FAS and pulmonary fibrosis: In addition, functionalized biocompatible surfaces with agonistic anti-Fas in extracorporeal immune therapy may be more suitable than systemic application of anti-Fas because the latter approach has been shown to have severe side effects such as liver toxicity and pulmonary fibrosis [32,33].